Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
Head & Neck Institute, Cleveland Clinic, Cleveland, OH, USA.
Oral Oncol. 2024 Oct;157:106957. doi: 10.1016/j.oraloncology.2024.106957. Epub 2024 Jul 16.
Advancements in immunotherapy for recurrent head and neck cancer have necessitated a better understanding of salvage surgical outcomes. This study aimed to determine patterns of failure following salvage head and neck surgery.
A retrospective cohort study was conducted of 280 patients who underwent salvage surgery for recurrent mucosal squamous cell carcinoma from 1997 to 2018. Cumulative incidence was calculated using the nonparametric Aalen-Johansen estimator. Time to recurrence (TTR) and overall survival (OS) were estimated using the Kaplan-Meier method and multivariable Cox proportional hazard models were used to evaluate associated factors.
The 2 and 5-year cumulative incidence rates of second recurrence were 48.3 % (95 % CI 42.4-54.3) and 54.9 % (95 % CI 48.9-60.8), respectively. At 5 years, second locoregional recurrence was twice as common as distant recurrence (41.5 % [95 % CI 35.6-47.4] vs. 21.7 % [95 % CI 16.8-26.6]). The median TTR was 21.1 months (95 % CI 4.4-34.8), which varied by site (38.2 larynx/hypopharynx, 13.9 oral cavity, 8.3 sinonasal, and 7.8 oropharynx, P=.0001). The median OS was 32.1 months (95 % CI 24.1-47.6) and was worse for patients who were Black (hazard ratio [HR] 2.15, 95 % CI 1.19-3.9), current smokers (HR 2.73, 95 % CI 1.53-4.88), former smokers (HR 2.00, 95 % CI 1.19-3.35), ≥ 60 years of age (HR 1.41, 95 % CI 1.01-1.97), or received multimodal primary therapy (HR 1.98, 95 % CI 1.26-3.13).
Rates of recurrence and mortality after salvage surgery were poor but worse for patients who were Black, older, smoked, had initial multimodal therapy, or had sinonasal or oropharyngeal cancers.
头颈部复发性肿瘤免疫治疗的进展使得人们对挽救性手术的结果有了更深入的了解。本研究旨在确定挽救性头颈部手术后的失败模式。
回顾性队列研究纳入了 1997 年至 2018 年间接受挽救性手术治疗复发性黏膜鳞状细胞癌的 280 例患者。使用非参数 Aalen-Johansen 估计法计算累积发生率。使用 Kaplan-Meier 法估计复发时间(TTR)和总生存期(OS),并使用多变量 Cox 比例风险模型评估相关因素。
术后 2 年和 5 年的二次复发累积发生率分别为 48.3%(95%CI 42.4-54.3)和 54.9%(95%CI 48.9-60.8)。5 年内,局部区域二次复发的发生率是远处复发的两倍(41.5%[95%CI 35.6-47.4]vs.21.7%[95%CI 16.8-26.6])。中位 TTR 为 21.1 个月(95%CI 4.4-34.8),不同部位 TTR 不同(喉/下咽 38.2%,口腔 13.9%,鼻窦 8.3%,口咽 7.8%,P=0.0001)。中位 OS 为 32.1 个月(95%CI 24.1-47.6),黑人患者(风险比[HR]2.15,95%CI 1.19-3.9)、当前吸烟者(HR 2.73,95%CI 1.53-4.88)、曾经吸烟者(HR 2.00,95%CI 1.19-3.35)、≥60 岁(HR 1.41,95%CI 1.01-1.97)或接受初始多模式治疗的患者(HR 1.98,95%CI 1.26-3.13)的 OS 更差。
挽救性手术后的复发和死亡率仍然较高,但黑人、年龄较大、吸烟、初始接受多模式治疗或患有鼻窦或口咽癌的患者情况更差。